Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bolaget.

Datum Källa Rubrik Typ Alternativ
2019-06-18 Cellink Cellink AB: CELLINK has completed a directed share issue of SEK 148.5 million Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 18 Jun 2019 | Cellink

Cellink AB: CELLINK has completed a directed share issue of SEK 148.5 million

The Board of Directors of CELLINK AB (publ) (”CELLINK” or the ”Company”) has, based on the authorization given by the Company’s Annual General Meeting that was held on 13 December 2018, resolved on a directed share issue of 550,000 new shares of series B (corresponding to approximately 6.5 per cent of the total number of outstanding shares in the Company) at a subscription price of SEK 270.00 per share (the ”Issue”), which means that the Company receives SEK 148,500,000.00 before transaction costs. The subscription price in the Issue has been determined through an accelerated bookbuilding procedure and corresponds to a discount of approximately 5.9 percent compared to the closing price on Nasdaq First North on 18 June 2019. The Issue was heavily oversubscribed and in addition to participation from existing shareholders, several new institutional investors subscribed in the Issue.

The Company is engaged in advanced discussions and has entered into a letter of intent to acquire a fast-growing (revenue CAGR 2016-2018 of 61 per cent) German laboratory equipment company active in the same niche as CELLINK with complimentary products and clear synergies between the two companies. The target company and CELLINK will be able to offer a stronger product offering to customers and provide complete solutions that are expected to drive both instrument sales as well as reagents and consumables sales. The target company’s customer base consists mainly of big pharma companies, which could further accelerate the Company’s growth in this customer segment. The target company had revenues of approximately EUR 3.5 million and an EBITDA of approximately EUR 1.4 million during the twelve-month period ending 31 March 2019 (applying CELLINK’s accounting principles). The acquisition price is preliminary set to an enterprise valuation of EUR 29 million and is intended to be financed through a combination of an issue in kind (EUR 20.0 million) to the sellers at an issue price of approximately SEK 297.17 and proceeds from the Issue (EUR 11.5 million). The target company has a net cash position of approximately EUR 2.5 million.

Furthermore, CELLINK has identified several other potential acquisitions. If the acquisition referred to in the letter of intent for some reason is not closed, the net proceeds from the Issue is intended to be used for other acquisitions.

The Board of Directors of CELLINK has decided to deviate from the shareholders’ pre-emption rights to ensure the most time and cost-effective financing of its M&A agenda.

The Issue entails a dilution of approximately 6.1 percent of the share capital in relation to the number of shares in CELLINK after the Issue, through an increase in the number of outstanding shares by 550,000 from 8,521,516 to 9,071,516 and a share capital increase by SEK 55,000.00 from SEK 852,151.60 to SEK 907,151.60.

Members of the board and the management team, of which several are large shareholders in CELLINK, have entered into lock-up agreements to, subject to customary exceptions, not sell shares in CELLINK for a period of 180 calendar days after the settlement date. Furthermore, the Company has agreed to a commitment, with customary exceptions (including an exception for the planned issue in kind mention above), not to carry out any additional future share issuances for a period of 180 calendar days after the settlement date.

Advisers

In conjunction with the Issue, the Company has engaged Carnegie Investment Bank as sole bookrunner and Advokatfirman Vinge as legal adviser.

For further information, please contact:

Erik Gatenholm, CEO

Phone (Sweden): +46 73 267 00 00

Phone (US): +1 (650) 515 5566

Email: eg@cellink.com

Gusten Danielsson, CFO

Phone (Sweden): +46 70 991 86 04

Phone (US): +1 (857) 332 2138

Email: gd@cellink.com

This is information that CELLINK AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 18 June 2019 at 21:55 CEST.

About CELLINK

CELLINK is the leading 3D-bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the Company’s certified adviser, available by phone at +46 846 383 00 and by email at: certifiedadviser@penser.se.

Important information
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in CELLINK in any jurisdiction, not from CELLINK or from any other person. Publication, distribution or release of this press release may, in certain jurisdictions, be subject to restrictions by law and the persons in such jurisdictions where this press release has been published or distributed should inform themselves of and follow such legal restrictions. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the ”Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

This press release is not a prospectus for the purposes of Directive 2003/71/EC (the ”Prospectus Directive”) and has not been approved by any regulatory authority in any jurisdiction. CELLINK has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Directed Issue. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive.

This press release may in the United Kingdom, be distributed and directed only to ”qualified investors” as defined as (i) professional investors as set out in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ”Order”); or (ii) fall within Article 49(2)(a) to (d) (”entities with high net worth” etc.) of the Order, (all such persons together being referred to as ”Relevant Persons”). An investment or investment activity to which this communication relates in the United Kingdom is available only to Relevant Persons and will only be carried out with Relevant Persons. Persons that are not Relevant Persons should not take any action based on this press release and should not act or rely on it.

The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zeeland, Singapore, South Africa, the United States, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction.

The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.

Forward-looking statements
This press release contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations about and targets for the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as ”believe”, ”expect”, ”anticipate”, ”intend”, ”may”, ”plan”, ”estimate”, ”will”, ”should”, ”could”, ”aim” or ”might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this press release. The information, opinions and forward-looking statements contained in this press release speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release

2019-06-18 Cellink Cellink AB: CELLINK har genomfört en riktad nyemission om 148,5 miljoner kronor Pressreleaser Ladda ner | Visa Stäng
2019-06-18 Cellink Cellink AB: CELLINK avser att genomföra en riktad nyemission av cirka 500 000 aktier av serie B för att finansiera ett möjligt förvärv Pressreleaser Ladda ner | Visa Stäng
2019-06-18 Cellink Cellink AB: CELLINK announces intention to carry out a directed share issue of approximately 500,000 shares of series B to finance a potential acquisition Pressreleaser Ladda ner | Visa Stäng
2019-05-27 Cellink Cellink AB: CELLINK del av samarbete för att förbättra behandlingen för brännskadade Pressreleaser Ladda ner | Visa Stäng
2019-05-27 Cellink Cellink AB: CELLINK joins collaboration to improve treatment for burn patients Pressreleaser Ladda ner | Visa Stäng
2019-05-03 Cellink Cellink AB: CELLINK's commercialized technology featured on the cover of Science Magazine Pressreleaser Ladda ner | Visa Stäng
2019-05-03 Cellink Cellink AB: CELLINK's kommersialiserade teknologi visas på omslaget av Science Magazine Pressreleaser Ladda ner | Visa Stäng
2019-05-02 Cellink Cellink AB: CELLINK lanserar nya vävnadsmodellkit Pressreleaser Ladda ner | Visa Stäng
2019-05-02 Cellink Cellink AB: CELLINK launches new tissue model kits Pressreleaser Ladda ner | Visa Stäng
2019-04-24 Cellink Cellink AB: CELLINK BIO X vinner stora designpriset 2019 Pressreleaser Ladda ner | Visa Stäng
2019-04-24 Cellink Cellink AB: CELLINK BIO X wins the Grand Award of Design. Pressreleaser Ladda ner | Visa Stäng
2019-04-10 Cellink Cellink AB: CELLINK visar fortsatt tillväxt och förbättrade marginaler i andra kvartalet (december 2018-februari 2019) Rapporter Ladda ner | Visa Stäng
2019-04-10 Cellink Cellink AB: CELLINK report continued growth and improved margins in the second quarter (December 2018-February 2019) Rapporter Ladda ner | Visa Stäng
2019-03-22 Cellink Cellink AB: CELLINK och forskningscentret för vuxna stamceller vid Seoul nationella universitet tillkännager nytt samarbete inom bioprintningsforskning Pressreleaser Ladda ner | Visa Stäng
2019-03-22 Cellink Cellink AB: CELLINK and the Adult Stem Cell Research Center at Seoul National University announce new agreement for bioprinting research Pressreleaser Ladda ner | Visa Stäng
2019-03-18 Cellink Cellink AB: CELLINK launches new product for Digital Light Processing 3D bioprinting Pressreleaser Ladda ner | Visa Stäng
2019-03-18 Cellink Cellink AB: CELLINK lanserar ny produkt för digital ljusbehandling 3D bioprinting Pressreleaser Ladda ner | Visa Stäng
2019-02-19 Cellink Cellink AB: CELLINK has been granted a patent for "3D printer and a method for 3D printing of a construct" from the Swedish Patent office Pressreleaser Ladda ner | Visa Stäng
2019-02-19 Cellink Cellink AB: CELLINK beviljas patent för "3D printer and a method for 3D printing of a construct" från PRV Pressreleaser Ladda ner | Visa Stäng
2019-02-04 Cellink CELLINK launches new product to bring fast and sharp live-cell imaging to every incubator Pressreleaser Ladda ner | Visa Stäng
2019-02-04 Cellink CELLINK lanserar ny produkt inom realtids cellmikroskopi som förenklar bioprintingprocessen Pressreleaser Ladda ner | Visa Stäng
2019-01-28 Cellink CELLINK with partner has been granted project funding of SEK 10 million from the EU for the FUNC project. CELLINK's share amounts to SEK 5 million Pressreleaser Ladda ner | Visa Stäng
2019-01-28 Cellink CELLINK med partner har beviljats projektfinansiering om 10 MSEK från EU för projektet FUNC. CELLINKs andel uppgår till 5 MSEK Pressreleaser Ladda ner | Visa Stäng
2019-01-22 Cellink Interim financial report 1, September - November 2018: Continued growth and improved margins Rapporter Ladda ner | Visa Stäng
2019-01-22 Cellink Delårsrapport 1, september-november 2018: Fortsatt tillväxt och förbättrade marginaler Rapporter Ladda ner | Visa Stäng
2018-12-14 Cellink Kommuniké från årsstämma den 13 december 2018 Pressreleaser Ladda ner | Visa Stäng
2018-12-14 Cellink Communication from the Annual General Meeting on December 13, 2018 Pressreleaser Ladda ner | Visa Stäng
2018-12-07 Cellink Handelsbanken Fonder and AP4 buy shares in CELLINK from the founders Pressreleaser Ladda ner | Visa Stäng
2018-12-07 Cellink Handelsbanken Fonder och AP4 köper aktier i CELLINK från grundarna Pressreleaser Ladda ner | Visa Stäng
2018-12-05 Cellink CELLINK and Prellis Biologics Inc. sign partnership to commercialize high-resolution holographic bioprinting technology for micro-printing Pressreleaser Ladda ner | Visa Stäng
2018-12-05 Cellink CELLINK och Prellis Biologics Inc. tecknar partnerskap för att kommersialisera holografisk bioprintingteknik med hög upplösning för mikroutskrift Pressreleaser Ladda ner | Visa Stäng
2018-12-04 Cellink CELLINK announces collaboration with MedImmune to utilize CELLINKs' 3D-Bioprinting technology for drug discovery Pressreleaser Ladda ner | Visa Stäng
2018-12-04 Cellink CELLINK tillkännager samarbete med MedImmune med syfte att utnyttja CELLINKs 3D-bioprinting-teknik för nya läkemedelsupptäckter Pressreleaser Ladda ner | Visa Stäng
2018-11-30 Cellink CELLINK has entered into an agreement to acquire the Biodispensing company Dispendix GmbH Pressreleaser Ladda ner | Visa Stäng
2018-11-30 Cellink CELLINK ingår avtal om förvärv av biodispenseringsbolaget Dispendix GmbH Pressreleaser Ladda ner | Visa Stäng
2018-11-14 Cellink CELLINK publishes annual report for 2017/2018 Rapporter Ladda ner | Visa Stäng
2018-11-14 Cellink CELLINK publicerar årsredovisning för 2017/2018 Rapporter Ladda ner | Visa Stäng
2018-11-14 Cellink Kallelse till årsstämma i CELLINK AB Pressreleaser Ladda ner | Visa Stäng
2018-11-06 Cellink CELLINK LANSERAR NYA BIOBLÄCK Pressreleaser Ladda ner | Visa Stäng
2018-11-06 Cellink CELLINK IS LAUNCHING NEW BIOINKS Pressreleaser Visa Stäng
2018-10-24 Cellink CELLINK offentliggör Bokslutskommuniké och rapport för 4:e kvartalet Rapporter Ladda ner | Visa Stäng
2018-10-24 Cellink Interim financial report 4 for the period 1st of June - 31st of August and the report for the full fiscal year Rapporter Ladda ner | Visa Stäng
2018-10-17 Cellink CELLINK IS LAUNCHING NEW BIOINKS Pressreleaser Ladda ner | Visa Stäng
2018-10-17 Cellink CELLINK LANSERAR NYA BIOBLÄCK Pressreleaser Ladda ner | Visa Stäng
2018-10-03 Cellink CELLINK och partners har beviljats projektfinansiering om 5,700 000 EURO från EU för projektet GIOTTO. CELLINKs andel uppgår till 300 000 EURO Pressreleaser Ladda ner | Visa Stäng
2018-10-03 Cellink CELLINK and partners have been granted project financing from EU totaling €5,700,000 for the Giotto project. CELLINKs portion of the grant is €300,000 Pressreleaser Ladda ner | Visa Stäng
2018-09-11 Cellink CELLINK brings on world distinguished scientist Dr. Mina J. Bisell to advisory board Pressreleaser Ladda ner | Visa Stäng
2018-09-11 Cellink CELLINK värvar den världsberömda forskaren Dr. Mina J. Bisell till sin Advisory Board Pressreleaser Ladda ner | Visa Stäng
2018-09-04 Cellink CELLINK's bioink and bioprinters are being used in several progressive research areas Pressreleaser Ladda ner | Visa Stäng
2018-09-04 Cellink CELLINK's biobläck och bioprinters används i flera olika progressiva forskningsområden Pressreleaser Ladda ner | Visa Stäng
2018-08-27 Cellink CELLINK launches new bioink series based on laminins Pressreleaser Ladda ner | Visa Stäng
2018-08-27 Cellink CELLINK lanserar ny biobläck-serie baserad på lamininer Pressreleaser Ladda ner | Visa Stäng
2018-07-16 Cellink CELLINK to receive €2.5 million grant from EU for the development and commercializing project "TumorPrint " Pressreleaser Ladda ner | Visa Stäng
2018-07-16 Cellink CELLINK beviljades 2,5 miljoner euro i finansiering från EU för utvecklings- och kommersialiseringsprojektet "TumorPrint" Pressreleaser Ladda ner | Visa Stäng
2018-07-11 Cellink Quarterly report 3 for the period 1st of March - 31st of May and for the first 9 months Rapporter Ladda ner | Visa Stäng
2018-07-11 Cellink CELLINK offentliggör kvartalsrapport för tredje kvartalet samt rapport för första 9-månaderna Rapporter Ladda ner | Visa Stäng
2018-07-04 Cellink CELLINK kund möjliggör kontrollerad cellformation Pressreleaser Ladda ner | Visa Stäng
2018-07-04 Cellink CELLINK Collaborator Enables Controlled Cell Formation Pressreleaser Ladda ner | Visa Stäng
2018-06-04 Cellink CELLINK har genomfört en riktad nyemission om cirka 100 miljoner kronor Pressreleaser Ladda ner | Visa Stäng
2018-06-04 Cellink CELLINK has completed a directed share issue of approximately SEK 100 million Pressreleaser Ladda ner | Visa Stäng
2018-06-04 Cellink CELLINK avser genomföra en riktad nyemission av aktier av serie B Pressreleaser Ladda ner | Visa Stäng
2018-06-04 Cellink CELLINK intends to make a directed share issue of Class B shares Pressreleaser Ladda ner | Visa Stäng
2018-06-01 Cellink CELLINK customer and technology user at Newcastle University 3D-Bioprinted first human corneas in cutting edge breakthrough Pressreleaser Ladda ner | Visa Stäng
2018-06-01 Cellink CELLINK kund- och teknikanvändare vid Newcastle University 3D Bioprintar första mänskliga hornhinnorna i banbrytande genombrott Pressreleaser Ladda ner | Visa Stäng
2018-05-11 Cellink CELLINK mottar order om 3,5 MSEK från distributör Pressreleaser Ladda ner | Visa Stäng
2018-05-11 Cellink CELLINK receives 3.5 MSEK order from distributor Pressreleaser Ladda ner | Visa Stäng
2018-05-04 Cellink CELLINK Collaborator 3D-Bioprinted Human Heart Valve Disease Models Using Nanoindentation-Based Biomechanics Pressreleaser Ladda ner | Visa Stäng
2018-05-04 Cellink CELLINK samarbetspartner 3D-Bioprintade Humana Hjärtvalvsjukdomsmodeller med Nanoindentationsbaserad biomekanik Pressreleaser Ladda ner | Visa Stäng
2018-05-03 Cellink CELLINK AB byter Certified Adviser till Erik Penser Bank AB Pressreleaser Ladda ner | Visa Stäng
2018-05-02 Cellink CELLINK lanserar ny pedagogisk plattform för bioprinting: CELLINK GO - Framtagen för att Revolutionera utbildningen Pressreleaser Ladda ner | Visa Stäng
2018-05-02 Cellink CELLINK launches new educational platform for Bioprinting: CELLINK GO - Made to Revolutionize Education Pressreleaser Ladda ner | Visa Stäng
2018-04-23 Cellink CELLINK appoints Carnegie Investment Bank AB (publ) as financial adviser Pressreleaser Ladda ner | Visa Stäng
2018-04-23 Cellink CELLINK utser Carnegie Investment Bank AB (publ) till finansiell rådgivare Pressreleaser Ladda ner | Visa Stäng
2018-04-19 Cellink CELLINK ingår partnerskap med ARMI BioFab USA, UNH Manchester för regenerativtillverkningsevenemang Pressreleaser Ladda ner | Visa Stäng
2018-04-13 Cellink CELLINK releases 7 new Bioinks, 3 new Kits, and standardized GelMA, to Enable the Bioprinting of Multifaceted Vascularized Constructs such as Skin Pressreleaser Ladda ner | Visa Stäng
2018-04-13 Cellink CELLINK lanserar 7 nya Biobläck, 3 nya kits med GelMA samt möjliggör 3D-Bioprinting av mångfasetterade vaskulära nätverk Pressreleaser Ladda ner | Visa Stäng
2018-04-11 Cellink CELLINK offentliggör kvartalsrapport för andra kvartalet samt halvårsresultat Rapporter Ladda ner | Visa Stäng
2018-04-09 Cellink CELLINK VINNER RED DOT AWARD FÖR BIO X Pressreleaser Ladda ner | Visa Stäng
2018-04-09 Cellink CELLINK WINS RED DOT AWARD FOR BIO X Pressreleaser Ladda ner | Visa Stäng
2018-03-19 Cellink CELLINK publishes article about bioink together with world renowned scientists Pressreleaser Ladda ner | Visa Stäng
2018-03-19 Cellink CELLINK publicerar artikel om biobläck tillsammans med världsledande forskare Pressreleaser Ladda ner | Visa Stäng
2018-02-08 Cellink CELLINK lanserar CELLINK X Bioinks Pressreleaser Ladda ner | Visa Stäng
2018-02-08 Cellink CELLINK launches the CELLINK X Bioink Series Pressreleaser Ladda ner | Visa Stäng
2018-02-01 Cellink CELLINK öppnar kontor på Kyoto University i Japan Pressreleaser Ladda ner | Visa Stäng
2018-02-01 Cellink CELLINK opens office at Kyoto University in Japan Pressreleaser Ladda ner | Visa Stäng
2018-01-17 Cellink CELLINK establishes R&D lab in AstraZeneca's BioVentureHub Pressreleaser Ladda ner | Visa Stäng
2018-01-17 Cellink CELLINK etablerar ett forsknings- och utvecklingslaboratorie i AstraZenecas BioVentureHub Pressreleaser Ladda ner | Visa Stäng
2018-01-17 Cellink Quarterly report 1 for the period 1st of September - 30th of November Rapporter Ladda ner | Visa Stäng
2018-01-17 Cellink Kvartalsrapport 1 (Q1) för 1 september 2017 - 30 november 2017 Rapporter Ladda ner | Visa Stäng
2018-01-08 Cellink CELLINK ingår ett samarbetsavtal med CTIBIOTECH för att skriva ut patientspecifika cancertumörer Pressreleaser Ladda ner | Visa Stäng
2018-01-08 Cellink CELLINK signs collaboration agreement with CTIBIOTECH for Bioprinting of patient-specific cancer tumors Pressreleaser Ladda ner | Visa Stäng
2017-12-20 Cellink Kommuniké från årsstämma den 14 december Pressreleaser Ladda ner | Visa Stäng
2017-11-27 Cellink CELLINK has been granted project funding from Horizon 2020 Pressreleaser Ladda ner | Visa Stäng
2017-11-27 Cellink CELLINK har blivit beviljat projektfinansiering från Horizon 2020 Pressreleaser Ladda ner | Visa Stäng
2017-11-16 Cellink Publicering av CELLINKs årsredovisning för 2016/2017 Rapporter Ladda ner | Visa Stäng
2017-11-15 Cellink CELLINK ingår ett utvecklingssamarbete med Takara Bio Pressreleaser Ladda ner | Visa Stäng
2017-11-15 Cellink CELLINK enters a collaborative research program with Takara Bio Pressreleaser Ladda ner | Visa Stäng
2017-10-19 Cellink End of the year report for the period 1 of September - 31st of August and Quarterly report 4 Rapporter Ladda ner | Visa Stäng
2017-10-19 Cellink Bokslutskommuniké för 1 september 2016 - 31 augusti 2017 samt kvartalsrapport 4 Rapporter Ladda ner | Visa Stäng
2017-10-06 Cellink CELLINK closes a directed share issue of SEK 30 million to Handelsbanken Fonder Pressreleaser Ladda ner | Visa Stäng
2017-10-06 Cellink CELLINK genomför riktad nyemission av B-aktier om 30 MSEK till Handelsbanken Fonder Pressreleaser Ladda ner | Visa Stäng
2017-09-27 Cellink CELLINK tecknar samarbetsavtal med MIT Pressreleaser Ladda ner | Visa Stäng
2017-09-27 Cellink CELLINK signs collaboration agreement with MIT Pressreleaser Ladda ner | Visa Stäng
2017-09-25 Cellink CELLINK receives design patent Pressreleaser Ladda ner | Visa Stäng
2017-09-25 Cellink CELLINK beviljas mönsterskydd Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

24 Oct 2018 | Bokslutskommuniké 2018
13 Dec 2018 | Årsstämma 2018
14 Dec 2018 | Årligutdelning
10 Apr 2019 | Kvartalsrapport 2019-Q2
11 Jul 2019 | Kvartalsrapport 2019-Q3
24 Oct 2019 | Bokslutskommuniké 2019
18 Dec 2019 | Årsstämma 2019

ca.penser.se använder cookies för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder cookies. Vad är cookies?

Jag godkänner